Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions.
Cardiovascular prevention
DASH diet
Heart failure
Hypertension
Lipoprotein(a)
Sotagliflozin
Journal
Current atherosclerosis reports
ISSN: 1534-6242
Titre abrégé: Curr Atheroscler Rep
Pays: United States
ID NLM: 100897685
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
25
04
2022
pubmed:
29
5
2022
medline:
15
7
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
Focused review highlighting select studies presented at the 2022 American College of Cardiology (ACC) Scientific Sessions. Included studies assessed the impact of a low-sodium diet on heart failure outcomes (SODIUM-HF); outcomes of pregnant patients with chronic hypertension treated with antihypertensive therapies (CHAP); cardiovascular outcomes in patients with type 2 diabetes and renal impairment treated with sotagliflozin (SCORED); a safety and efficacy study investigating SLN360, a short interfering RNA targeting lipoprotein(a) (APOLLO); a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure reduction from the SPYRAL HTN-ON MED pilot study. Research presented at the 2022 ACC Scientific Sessions underscores the new potential and meaningful impact of cardiovascular disease prevention and management interventions.
Identifiants
pubmed: 35633463
doi: 10.1007/s11883-022-01042-6
pii: 10.1007/s11883-022-01042-6
pmc: PMC9142342
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
671-680Informations de copyright
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
N Engl J Med. 2022 May 12;386(19):1781-1792
pubmed: 35363951
Curr Atheroscler Rep. 2022 Jan;24(1):61-72
pubmed: 35080715
Curr Atheroscler Rep. 2021 Oct 14;23(12):76
pubmed: 34648072
Lancet. 2022 May 7;399(10337):1799-1808
pubmed: 35390321
Lancet. 2018 Jun 9;391(10137):2346-2355
pubmed: 29803589
Obstet Gynecol. 2019 Jan;133(1):e26-e50
pubmed: 30575676
JAMA. 2022 May 3;327(17):1679-1687
pubmed: 35368052
N Engl J Med. 2021 Jan 14;384(2):129-139
pubmed: 33200891
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Curr Atheroscler Rep. 2021 Jun 19;23(8):41
pubmed: 34146181
Prog Cardiovasc Dis. 2022 Jan 19;:
pubmed: 35063437
Cardiovasc Drugs Ther. 2021 Dec;35(6):1269-1279
pubmed: 32997212
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Am Heart J. 2022 Jun;248:21-34
pubmed: 35218725
Curr Atheroscler Rep. 2021 Jul 6;23(9):50
pubmed: 34226979
Am J Obstet Gynecol. 2012 Feb;206(2):134.e1-8
pubmed: 22177190
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008722
pubmed: 23450587